Epithalon complete guide

Epithalon — the synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG), also written Epitalon in transliterated Russian sources — is one of the most-cited compounds in the post-Soviet gerontology research corpus. It was first synthesized in the 1980s by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology as a structural analog of the active fraction of epithalamin, a low-molecular-weight peptide complex extracted from bovine pineal glands. Where epithalamin is a complex mixture, Epithalon is a single defined four-residue peptide — small enough to be synthesized chemically, characterized analytically, and tested across the cell-culture, animal-model and clinical-research designs that the Khavinson laboratory has accumulated over four decades.

This guide is a mechanism-focused deep-dive: what AEDG is structurally, the proposed mechanism of action through telomerase activation and gene-expression modulation, the body of telomere-length and cellular-aging research published predominantly in the Russian gerontology literature, how Epithalon sits relative to the broader Khavinson-peptide family, and how it differs mechanistically from NAD+ in the context of cellular-aging research. Everything is research-frame language. No protocol guidance. No clinical recommendations.

Quick reference — Epithalon identifiers

Property	Epithalon
Class	Synthetic tetrapeptide pineal-gland analog
Sequence	AEDG — Ala-Glu-Asp-Gly
Molecular formula	C14H22N4O9
Molecular weight	390.35 g/mol
CAS	307297-39-8
Origin	Synthetic analog of the pineal-gland peptide complex epithalamin, designed at the Khavinson laboratory (St. Petersburg Institute of Bioregulation and Gerontology)
Plasma half-life	Short — minutes-to-hours range, characteristic of small unmodified peptides
Vial strengths (TogoPeptide)	10 mg lyophilized; also bundled in the Longevity Stack

Origin and structure — pineal-gland peptide analog

The starting point is epithalamin — a peptide complex extracted from bovine pineal glands and characterized by the Khavinson group from the late 1970s onward. The pineal gland was a deliberate target: post-Soviet gerontology research had identified it as a candidate “ageing pacemaker” organ, and extracts of pineal tissue were documented to modulate circadian, neuroendocrine and immune phenotypes in research-animal models. Epithalamin was the active fraction. The problem was that it remained a complex of multiple peptides, hard to standardize and hard to characterize at the molecular level.

The solution was a defined-sequence synthetic analog. Khavinson and colleagues fractionated epithalamin, identified short peptide sequences associated with its activity, and synthesized AEDG — alanine-glutamate-aspartate-glycine — as a four-residue compound encoding the proposed bioactive motif. At 390 g/mol Epithalon is small enough to be soluble and stable as lyophilized powder, small enough to be plausibly orally bioavailable in the published research-animal designs, and small enough that the structural rationale for crossing biological barriers (including the blood-brain barrier in some research models) is at least defensible.

Epithalon sits in a broader family of Khavinson peptides — short defined-sequence peptides synthesized as analogs of tissue-extract peptide complexes. Sister compounds include Vilon (Lys-Glu, immune-tissue analog), Pinealon (Glu-Asp-Arg, neuroprotection-focused), Cortagen (Ala-Glu-Asp-Pro, brain-cortex analog), and Thymalin-derived sequences (thymic-tissue peptides). The shared design philosophy: take a peptide-complex extract from the tissue of interest, fractionate down to bioactive short sequences, and synthesize them defined.

Mechanism — gene expression and telomerase

The proposed mechanism of Epithalon, as developed across the Khavinson-laboratory publications, sits at the intersection of telomere biology and gene-expression regulation. The proposed model is unusual in that it does not invoke a classical receptor; it invokes direct or near-direct interaction between the tetrapeptide and chromatin/DNA.

Telomerase activation research

The canonical published-research finding is that Epithalon up-regulates expression of telomerase reverse transcriptase (TERT), the catalytic subunit of telomerase, in cultured human somatic cells [2]. Telomerase is the ribonucleoprotein enzyme complex that synthesizes telomeric repeat sequences (TTAGGG in vertebrates) at chromosome ends. Most somatic cells silence telomerase after embryogenesis and consequently lose telomeric DNA across each round of division — the classical “end-replication problem” mechanism behind the Hayflick replicative limit.

In published Khavinson-laboratory research, addition of Epithalon to cultured human somatic cells was documented to re-activate telomerase activity, lengthen telomere repeats over multiple passages, and extend the cell-culture replication horizon beyond the Hayflick boundary in some experimental designs [5]. This telomerase-activation finding is the best-known result associated with Epithalon and the basis of its positioning in the cellular-aging research conversation.

Gene-expression modulation

Beyond TERT, the published Epithalon research documents broader gene-expression effects. The Khavinson laboratory has advanced a site-specific peptide-DNA interaction hypothesis: that short peptides like AEDG bind directly to specific DNA sequences in promoter regions, modulating chromatin accessibility and transcription-factor recruitment in an allosteric fashion. The model is distinct from classical receptor-binding pharmacology — it places the peptide as a chromatin-level regulator rather than a cell-surface signaling agonist.

The proposed mechanism remains the subject of ongoing methodological discussion and is concentrated in the Russian and post-Soviet research lineage. It is not a fringe claim — it is published in peer-reviewed journals indexed on PubMed — but it sits in a different mechanistic framework than the receptor-pharmacology lineage that dominates Western drug development.

Pineal-gland melatonin axis

Because Epithalon is derived structurally from a pineal-gland peptide complex, a parallel research line documents its effects on melatonin secretion patterns in research-animal models. Published work documents Epithalon-associated normalization of age-disrupted melatonin rhythm — restoration of nocturnal melatonin peaks, improved phase-amplitude characteristics of circadian profiles, and modulation of pineal-gland gene expression. This places Epithalon in conversation with chronobiology and circadian-aging research lines, beyond the telomerase-centric framing.

Antioxidant and anti-inflammatory effects

A secondary mechanism layer documented in the published Khavinson-laboratory research includes reduced markers of oxidative stress (lipid peroxidation, protein-carbonyl content) and modulation of inflammatory cytokine profiles in research-animal designs. These effects are positioned as downstream consequences of the gene-expression modulation rather than as the primary mechanism, but they figure prominently in the published functional-outcome data on cellular and tissue ageing.

Telomere-length research literature

The cell-culture findings on TERT up-regulation and telomere lengthening have been complemented by research-animal-model work documenting lifespan-extension phenotypes in published Khavinson-laboratory designs. In aged-mouse and aged-rat models, chronic Epithalon administration has been associated with extended median and maximum lifespans, reduced age-associated tumor incidence in some genetic backgrounds, and preserved measures of physiological function into late life [6].

Important framing: these are research-animal-model findings, not human lifespan claims. The published work documents lifespan extension in inbred-strain rodent designs under controlled-vivarium conditions. Translation to human longevity is a separate question and one that has not been resolved in the published literature; the human-clinical research that exists is concentrated in older Russian-language gerontology-clinic publications and uses outcome measures that do not map cleanly onto Western trial-design conventions.

Cellular aging and biomarker research

Beyond telomere measurements, the published Epithalon research corpus documents effects on a panel of cellular-aging biomarkers. These include reduced senescence-associated β-galactosidase staining in aged-cell-culture designs, modulation of the p16^INK4a and p21 cell-cycle inhibitors associated with replicative senescence, improved DNA-repair capacity as measured in comet-assay and γ-H2AX-foci designs, and improved mitochondrial-function markers in aged-tissue research models. The biomarker work is complementary to the telomere literature — the proposition is that Epithalon modulates a network of cellular-aging endpoints rather than a single isolated mechanism [1].

Russian gerontology research lineage

Epithalon belongs to a distinct research tradition that benefits from explicit context. The St. Petersburg Institute of Bioregulation and Gerontology, founded in the Soviet period and led by Vladimir Khavinson for several decades, has produced one of the largest single-laboratory bodies of work on peptide bioregulation of ageing. Khavinson’s published output runs to several hundred peer-reviewed papers across PubMed-indexed journals, sustained collaborator networks across Russia, the United States, Germany, Italy and Spain, and a doctoral-training programme that has produced multiple second-generation researchers in the same line [3].

The relationship of this corpus to the Western longevity-research literature is best characterized as parallel and partially overlapping. Both lineages identify cellular ageing, mitochondrial function, telomere maintenance and gene-expression regulation as central themes. They differ in mechanistic vocabulary, in regulatory framework (the post-Soviet gerontology tradition operates outside the FDA/EMA drug-approval pathway), and in publication-venue distribution. Reading the Epithalon literature responsibly means engaging with it on its own methodological terms while noting that the Western-equivalent telomerase-pharmacology corpus is comparatively thin [4].

Epithalon vs NAD+ — different cellular-aging mechanisms

Both Epithalon and NAD+ are positioned in the cellular-aging research conversation, but they target the topic through entirely non-overlapping mechanisms. This is why both compounds appear in the Longevity Stack rather than as substitutes for each other.

Aspect	Epithalon	NAD+
Class	Synthetic tetrapeptide	Pyridine-nucleotide coenzyme
Molecular weight	390.35 g/mol	663.43 g/mol
Primary research mechanism	Telomerase (TERT) activation; site-specific peptide-DNA interaction; chromatin-level gene-expression modulation	Substrate for sirtuin deacetylases, PARP DNA-repair enzymes and CD38 hydrolases; obligate redox cofactor
Cellular endpoint	Telomere length, replicative-senescence biomarkers, pineal/melatonin axis	Mitochondrial respiration, sirtuin-mediated transcription, NAD+/NADH ratio
Research lineage	Khavinson laboratory, St. Petersburg, post-Soviet gerontology corpus	Guarente, Sinclair, Verdin laboratories; Western longevity-pharmacology corpus
Stack pairing rationale	Chromatin / telomere arm of cellular-aging research	Metabolic / mitochondrial / sirtuin arm of cellular-aging research

The two compounds are mechanistically orthogonal. Epithalon does not consume NAD+, does not act on sirtuins, and does not directly modulate the mitochondrial electron transport chain. NAD+ does not bind chromatin in a sequence-specific manner and does not directly modulate TERT expression. A research design probing “cellular ageing” with both compounds is probing two distinct biological axes simultaneously.

Storage and handling

Epithalon ships as lyophilized powder, typically white to off-white. Standard research-handling literature documents:

• Lyophilized state: sealed at −20°C, protected from light. Stable for the manufacturer-stated window when kept cold and dry.
• Diluent: bacteriostatic water (0.9% benzyl alcohol) is the standard reconstitution diluent for the published research-handling literature on small peptides of this class.
• Reconstituted state: refrigerate at 2–8°C and protect from light. Working window for reconstituted Epithalon is approximately 28 days under refrigeration in published research-handling guidance.
• Avoid freeze-thaw cycles after reconstitution. Repeated freeze-thaw degrades short peptides through both physical (aggregation) and chemical (deamidation, hydrolysis) routes.
• Light sensitivity: the aspartate and glutamate side-chain carboxylates are not strongly photo-active, but light protection during storage and handling remains best practice.

Each TogoPeptide Epithalon shipment includes a per-batch Certificate of Analysis with HPLC purity, mass-spectrometry identity confirmation, lot number, manufacture date, and analysis date. See how to read a COA or reconstitution methodology for the methodology details.

Cross-research lines and pairings

• Longevity Stack — cellular-aging research bundle: Epithalon + NAD+ + MOTS-c + SS-31 in a curated multi-mechanism design. Epithalon contributes the telomerase / chromatin / gene-expression arm; NAD+ contributes the sirtuin / mitochondrial-redox arm; MOTS-c contributes the mitochondrial-derived peptide signaling arm; SS-31 contributes inner-membrane cardiolipin protection. The four compounds target the cellular-aging research conversation through four non-overlapping mechanism classes.
• Reconstitution math: documented in the reconstitution calculator — Epithalon at 10 mg vial format with 390.35 g/mol molecular weight is a straightforward reconstitution exercise.
• Khavinson-peptide family: researchers working on Epithalon may also wish to investigate sister compounds from the same laboratory lineage — Pinealon (Glu-Asp-Arg), Vilon (Lys-Glu), Cortagen (Ala-Glu-Asp-Pro). Same design philosophy, different tissue-extract starting points.

Closing

Epithalon is the canonical example of the Khavinson-laboratory peptide-bioregulation research programme — a synthetic four-residue analog of a pineal-gland peptide complex, with a published research corpus documenting telomerase activation, gene-expression modulation through a proposed site-specific peptide-DNA interaction, and lifespan-extension phenotypes in research-animal models. Its mechanism vocabulary belongs to a research lineage parallel to but distinct from Western longevity pharmacology, and reading the literature on its own methodological terms is the responsible posture.

This guide documents what published peer-reviewed research has investigated. It is mechanism context for laboratory researchers, not therapeutic recommendation, not protocol guidance, not a basis for self-administration of any kind.

Source Epithalon for laboratory research:

• Epithalon product page — full identifiers, 10 mg lyophilized vial, per-batch COA
• Longevity Stack — curated Epithalon + NAD+ + MOTS-c + SS-31 bundle for cellular-aging research designs
• Longevity research compounds — full category listing

For methodology and laboratory-handling questions, contact our research-supply team at info@togopeptide.com.